Resources / 5: Diagnosis & Psychopathology / Neurocognitive Disorders

Maya inspects the bunny through a magnifying glass with a checklist in hand

Neurocognitive Disorders

5: Diagnosis & Psychopathology

Study guide by Anders Chan, PsyD · Updated

Understanding Neurocognitive Disorders: A Practical Guide for Future Psychologists

You're going to encounter patients with memory problems, confusion, and cognitive decline throughout your career. Some of them will have symptoms that developed overnight in a hospital room. Others will have families who've watched their loved one slowly fade over years. Understanding neurocognitive disorders isn't just about memorizing criteria. It's about recognizing patterns that will help you provide accurate diagnoses and appropriate care.

Let's break down this complex category into understandable pieces that will stick with you long after the exam.

What Makes Neurocognitive Disorders Different

Neurocognitive disorders all share one critical feature: acquired cognitive dysfunction. This means the person's brain was working normally at one point, and then something changed. We're not talking about developmental issues here. These are declines from a previous level of functioning.

The DSM-5-TR divides these disorders into three main groups: delirium (the acute crisis), mild neurocognitive disorder (noticeable problems that don't disrupt independence), and major neurocognitive disorder (significant impairment that interferes with daily living).

Major vs. mild, by the numbers:

Major NCDMild NCD
Test performance (typical)2 or more SD below norms (3rd percentile or below)1-2 SD below norms (3rd to 16th percentile)
Daily independenceNeeds help with complex daily tasks (paying bills, managing medications)Still independent, though tasks take more effort

Decline can involve any of six cognitive domains: complex attention, executive function, learning and memory, language, perceptual-motor, and social cognition. Dementia (roughly the same as major NCD) affects about 1%-2% of people at age 65 and as many as 30% by age 85.

Delirium: The Cognitive Emergency

Delirium is the disorder you'll see when something has gone seriously wrong, and it's happening fast. Think of it like your computer suddenly freezing and displaying error messages. Something in the system is critically malfunctioning right now.

Core Features You Must Know

Delirium requires two key components working together:

  1. Disturbed attention and awareness that develops quickly (hours to days), fluctuates throughout the day, and represents a clear change from the person's baseline

  2. At least one additional cognitive problem such as memory issues, language difficulties, disorientation, or perceptual disturbances

Here's what makes delirium distinctive: it comes on fast and changes throughout the day. Your patient might seem relatively coherent in the morning, then by evening they're confused about where they are and seeing things that aren't there.

Specifiers:

  • Course: acute (hours or days) or persistent (weeks or months)
  • Activity level: hyperactive (agitated, uncooperative), hypoactive (sluggish, lethargic, close to stupor), or mixed. The quiet, hypoactive type is the one most easily missed, because the person isn't disruptive

Prevalence: low in the community (1%-2%) but 18%-35% at hospital admission, and highest in hospitalized older adults.

What Causes It?

Delirium always has a physiological cause. Common culprits include:

  • High fever
  • Nutritional deficiencies
  • Electrolyte imbalances
  • Kidney or liver failure
  • Head injuries
  • Medications and substances (alcohol, lithium, sedatives, anticholinergic drugs)

It's most common in hospitalized older adults, which makes sense. They're dealing with medical crises, unfamiliar environments, disrupted sleep, and multiple medications all at once.

Treatment Approach

Your job is threefold: identify and address the underlying medical cause, reduce disorientation through environmental changes (adequate lighting, minimal noise, a clock and calendar, and encouraging regular visits from familiar family and friends), and potentially use antipsychotic medications like haloperidol to manage severe agitation or psychotic symptoms.

Nonpharmacological care comes first. NICE quality standards list steps like reorientation (a clock and calendar), familiar staff, regular visits from family and friends, walking, enough fluids, working hearing and visual aids, and quiet sleep periods. Multicomponent prevention programs like these cut delirium incidence by about 44% in randomized or matched trials. Antipsychotics, by contrast, did not change delirium incidence, duration, severity, or length of stay in a meta-analysis, so reserve them for severe agitation or distressing psychosis.

The Geography of Brain Damage: Cortical, Subcortical, and Mixed

Before we dive into specific disorders, you need to understand that where the damage occurs determines what symptoms you'll see. This is crucial for differential diagnosis.

LocationPrimary SymptomsExample Disorders
Cortical (cerebral cortex damage)Memory loss often first, aphasia, agnosia, apraxia, poor insightAlzheimer's disease, Frontotemporal NCD
Subcortical (basal ganglia, thalamus, brainstem)Cognitive slowing, apathy, depression, motor problems (speech, gait)Parkinson's, Huntington's, HIV-related NCD
Cortico-subcortical (both cortical and subcortical regions)Variable depending on affected areasVascular NCD, Lewy body disease, Creutzfeldt-Jakob

One caution on the cortical row: "memory loss often first" fits Alzheimer's. Frontotemporal NCD is also cortical, but it starts with behavior or language changes while memory is relatively spared.

Alzheimer's Disease: The Most Common Culprit

Alzheimer's is the most common cause of dementia: DSM-5-TR says it accounts for about 60% to over 90% of dementias (major NCD), depending on the setting and diagnostic criteria. It is found in 11% of people 65 and older and 32% of those 85 and older. If you remember nothing else, remember this disease inside and out.

Diagnostic Requirements

The person must meet criteria for mild or major NCD with these specific features:

  • Insidious onset (gradual, sneaky beginning)
  • Steady progression of symptoms
  • Impairment in one or more cognitive domains (for major NCD, at least two domains)
  • Can't be better explained by another disorder

The diagnosis comes in two confidence levels: "probable" and "possible." For probable Alzheimer's, you need either genetic evidence (testing or family history showing causative mutations) or both a clear decline in memory and learning plus at least one other domain and a steady, gradual decline without long plateaus. Since the September 2024 DSM-5-TR update, a second contributing cause (like vascular disease) no longer rules out probable; when two causes both contribute, the diagnosis is neurocognitive disorder due to multiple etiologies.

The "memory plus one other domain" rule belongs to probable Alzheimer's in major NCD. Mild NCD works differently:

  • Major NCD: probable if there is a causative genetic mutation, OR clear decline in memory/learning plus at least one other domain with steady, gradual progression. Otherwise, possible
  • Mild NCD: probable only with a causative genetic mutation. Without one, it is possible Alzheimer's (clear memory/learning decline with steady, gradual progression)

Who Gets It?

Some important patterns to know:

  • Age: Most common onset between 70-89 years old
  • Gender: Women show higher overall rates, though this may reflect longer lifespan rather than true increased risk
  • Race/ethnicity: Among adults 65+, Black Americans have the highest rates, followed by Hispanic Americans, then White Americans
  • Early-onset form: Can occur ages 40-59, often linked to known causative gene mutations

The Biology Behind the Disease

Here's where it gets interesting. Alzheimer's involves a toxic protein buildup that disrupts normal brain communication:

Amyloid plaques: Clumps of beta-amyloid protein that form outside neurons

Neurofibrillary tangles: Abnormal tau protein accumulation inside neurons that creates twisted threads

Think of plaques and tangles like accumulated junk mail and tangled cables behind your entertainment center. Individually annoying, but together they completely disrupt the system's ability to function.

The tangles follow a predictable path: they start in the medial temporal lobe (first the entorhinal region, then the hippocampus, your memory center), then spread to frontal and parietal lobes, and eventually throughout the cortex (Braak & Braak, 1991). Amyloid plaques take a different route: they appear first in the neocortex and reach the medial temporal lobe later (Thal et al., 2002).

The neurotransmitter problems are equally important: reduced acetylcholine (ACh) and excessive glutamate, both critical for learning and memory.

Alzheimer's vs. Depression with Cognitive Symptoms

This distinction trips up many students. The term "pseudodementia" describes depression that looks like dementia. Here's your comparison chart:

FeatureAlzheimer's DiseaseDepression with Cognitive Symptoms
OnsetGradual, insidiousAbrupt
AwarenessMinimizes or denies problemsExaggerates problems
Memory lossSevereModerate
Assessment responsesWrong answers, confabulation"I don't know"
Emotional presentationApathy, lack of motivationMelancholia, anxiety
Treatment responsePoorGood

The Three-Stage Journey

Understanding the progression helps with prognosis and treatment planning. DSM-5-TR puts mean survival after diagnosis at about 10 years, and some people live with the disease for 20 years. That figure partly reflects the advanced age of most patients rather than the disease alone.

Early Stage (2-4 years):

  • Short-term memory loss (usually the first red flag)
  • Difficulty recalling names (anomia)
  • Personality changes (often indifference)
  • Anxiety or depression
  • Poor concentration
  • Disorientation to time and space

Middle Stage (2-10 years):

  • Worsening short-term memory, now with long-term memory loss
  • Mood swings and irritability
  • Increasing disorientation
  • Hallucinations and delusions
  • Wandering and pacing
  • Repetitive speech and actions (perseveration)
  • Problems with daily activities (bathing, dressing)
  • Sundowning (evening confusion and agitation)

Late Stage (1-3 years):

  • Severely deteriorated cognition
  • Profound disorientation
  • Severely impaired communication
  • Loss of motor skills and self-care abilities
  • Incontinence
  • Abnormal reflexes and seizures
  • Frequent infections

Current Treatment Options

Alzheimer's disease has no cure. Each medicine has a different job.

Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors: they slow the breakdown of acetylcholine. Memantine acts on glutamate signaling through NMDA receptors. These drugs help manage symptoms. They do not remove amyloid plaques (Arvanitakis et al., 2019).

Lecanemab and donanemab are antibodies that target amyloid. They can slow decline in early Alzheimer's disease. They do not restore lost memory or stop the disease. Start treatment in the mild cognitive impairment or mild dementia stage, with confirmed amyloid buildup. Amyloid PET or a cerebrospinal fluid test can help confirm it. Memory complaints alone are not enough (van Dyck et al., 2023; Sims et al., 2023; Rabinovici et al., 2025).

Think of these drugs like brakes on a car rolling downhill. They slow the car down. They do not drive it back up the hill.

Lecanemab (Leqembi): Treatment can start with an IV infusion every 2 weeks or a weekly shot under the skin, called Leqembi IQLIK. The FDA approved the shot for starting treatment in July 2026. After 18 months, a person can keep the starting schedule or move to a lighter maintenance schedule (FDA, 2026a).

Donanemab (Kisunla): The FDA approved it in July 2024. It is given by IV infusion every 4 weeks. The dose goes up step by step over the first four infusions, a schedule the FDA revised in 2025. Doctors may stop it once an amyloid PET scan shows the plaques are down to very low levels. Stopping does not mean the disease is cured (FDA, 2024, 2025).

ARIA is the main safety warning. ARIA stands for amyloid-related imaging abnormalities. ARIA-E means swelling or fluid buildup in the brain. ARIA-H means tiny spots of bleeding. ARIA often causes no symptoms, but serious and even deadly cases have happened. Both drugs carry an FDA boxed warning. People with two copies of the APOE e4 gene have a higher risk, so genetic testing should be talked through before treatment. A baseline MRI and repeat MRIs help monitor risk. New headache, confusion, vision changes, or seizures during treatment need prompt medical assessment (FDA, 2025, 2026a).

Slower decline is not improvement. In the CLARITY AD trial, people on lecanemab got worse more slowly than people on placebo over 18 months. The difference was 0.45 points on the 18-point CDR-SB scale, about 27% less decline relative to placebo. Both groups still declined. A percentage only makes sense next to its scale, its time period, and its comparison group (van Dyck et al., 2023).

Agitation is a separate target. Brexpiprazole (Rexulti) gained FDA approval for agitation associated with Alzheimer's dementia in May 2023. Dextromethorphan-bupropion (Auvelity) got the same approval in April 2026. These drugs treat agitation. They do not remove amyloid or fix memory loss. Neither one is meant to be given only "as needed" (FDA, 2023, 2026b).

Aducanumab (Aduhelm) is history, not a current option. It got a fast-track (accelerated) approval in 2021, never earned full approval, and its application was withdrawn in November 2024 (FDA, 2026c).

Additional treatments include antidepressants for mood symptoms, anxiolytics for agitation, and antipsychotics for severe behavioral problems or psychosis. Use antipsychotics with caution: in older adults with dementia, atypical antipsychotics raised the risk of death about 1.6-1.7 times compared with placebo, and the FDA added a "black box" warning. Nonpharmacological approaches for behavior problems come first.

Don't overlook caregiver support. It's not just compassionate, it's clinically effective. Supported caregivers are less likely to place family members in nursing homes, and staying at home is associated with better patient outcomes.

Risk Factors You Should Know

  • Age is the strongest risk factor of all
  • APOE ε4 (apolipoprotein E4) is the strongest genetic susceptibility gene for typical late-onset Alzheimer's. It raises risk and lowers age at onset, especially with two copies, but it is a risk gene, not a cause: some people with two copies never develop symptoms, and the link is not consistent across all ethnic groups. Rare causative mutations on chromosomes 1, 14, and 21 cause early-onset, autosomal dominant forms
  • Low educational attainment
  • Obesity
  • Hearing loss
  • Down syndrome (due to extra APP gene on chromosome 21)
  • High neuroticism and low conscientiousness personality traits
  • Rapid deterioration in sense of smell (predicts onset)

Neurocognitive Disorder with Lewy Bodies: The Fluctuating Presentation

This disorder involves abnormal protein deposits (Lewy bodies) in the brain. It's distinguished by specific core and suggestive features.

Core Features (need 2 for probable, 1 for possible):

  • Fluctuating cognition with varying attention and alertness
  • Recurrent visual hallucinations
  • Parkinsonism symptoms that develop AFTER cognitive symptoms

Suggestive Features:

  • REM sleep behavior disorder symptoms
  • Severe sensitivity to antipsychotic medications

The full rule has two routes each:

  • Probable: 2 core features, OR 1 suggestive feature plus 1 or more core features
  • Possible: only 1 core feature, OR 1 or more suggestive features with no core feature

Key Distinction from Alzheimer's

In Lewy body disease, the early prominent symptoms are problems with complex attention, visuospatial processing, and executive function. In Alzheimer's, memory and learning deficits dominate early on.

Key Distinction from Parkinson's Disease

Both involve Lewy bodies, but timing matters:

  • Parkinson's disease NCD: Motor symptoms come FIRST, cognitive symptoms later
  • Lewy body NCD: Cognitive symptoms come FIRST (or simultaneous with motor symptoms)

The 1-year rule: to attribute dementia to Parkinson's disease, the Parkinson's diagnosis must be present for at least 1 year before cognitive decline reaches the level of major NCD. In Lewy body NCD, cognitive symptoms may begin before, with, or without parkinsonism.

Vascular Neurocognitive Disorder: When Blood Flow Problems Damage the Brain

This diagnosis requires three components:

  1. Meets criteria for major or mild NCD
  2. Symptoms consistent with vascular cause (temporal relationship to stroke or prominent attention/executive problems)
  3. Evidence of cerebrovascular disease from history, exam, or neuroimaging

The course varies dramatically: you might see acute onset with partial recovery, stepwise decline, or progressive deterioration with plateaus.

Prevention targets the risk factors: hypertension, heart disease, diabetes, obesity, high cholesterol, and smoking. It's like maintaining your car. Address the warning signs before the engine fails.

Frontotemporal Neurocognitive Disorder: The Early-Onset Personality Changer

DSM-5-TR calls this "a common cause" of early-onset NCD (before age 65), not "the most common." Alzheimer's also causes many early-onset cases (about 200,000 Americans had onset before 65 in 2016). People with frontotemporal NCD typically present in their 50s. What makes it distinctive is that memory and perception stay relatively intact early on, while behavior and language fall apart.

The Behavioral Variant (Most Common)

The behavioral variant makes up about 60% of cases. Look for prominent decline in social cognition and executive function, plus three or more of these:

  • Behavioral disinhibition (inappropriate social behavior)
  • Apathy and lack of initiative
  • Loss of sympathy or empathy
  • Perseverative or compulsive behaviors
  • Changes in eating (overeating, preferring sweets)

Imagine a colleague who was always professional suddenly making inappropriate comments in meetings, showing no concern when others are upset, and eating donuts compulsively during presentations. That dramatic personality change without memory problems points toward frontotemporal NCD.

The Language Variant (Primary Progressive Aphasia)

Prominent language decline involving problems with speech production, word finding, naming objects, grammar, or comprehension.

Critical Distinction from Alzheimer's

FeatureFrontotemporal NCDAlzheimer's Disease
Age of onsetOften before 65Usually 70-89
Early prominent symptomsPersonality changes, behavioral disinhibition, language problemsMemory impairment
Early memoryRelatively preservedSignificantly impaired
Early social behaviorSeverely disruptedInitially intact

Other Neurocognitive Disorders You Need to Know

NCD Due to Traumatic Brain Injury

Diagnostic requirements:

  • Criteria for major or mild NCD are met
  • Evidence of a traumatic brain injury (an impact to the head or rapid movement of the brain inside the skull) with at least one of: loss of consciousness, posttraumatic amnesia, disorientation and confusion, or neurological signs (such as injury on neuroimaging, visual field cuts, loss of smell, or weakness on one side)
  • The NCD appears immediately after the injury (or after the person regains consciousness) and persists past the acute post-injury period

Key facts:

  • Falls are the leading cause of TBI in the U.S., followed by being struck by or against objects, motor vehicle crashes, and assaults. Sports concussion is a growing cause of mild TBI
  • Men are about 40% more likely to have a TBI, except after age 65, when women may be at higher risk
  • Recovery tracks severity: complete recovery is typical after mild TBI, while recovery after moderate or severe TBI is more variable and often incomplete. Older age, lower pre-injury cognitive ability, pre-injury depression, and longer posttraumatic amnesia predict worse outcomes
  • Common symptoms include problems with complex attention, processing speed, executive function, learning and memory, and social cognition, plus irritability, sensitivity to light and sound, easy fatigue, and mood changes

TBI vs. acute stress disorder or PTSD: Re-experiencing and avoidance point to a trauma disorder. Persistent disorientation and confusion point to TBI. The two can co-occur after the same event.

HIV-Related NCD

Caused by HIV infection affecting the brain. Shows subcortical symptoms: forgetfulness, poor attention, cognitive slowing, psychomotor slowing, apathy, social withdrawal, tremors, clumsiness.

Prion Disease (Creutzfeldt-Jakob Disease)

The rapidly progressive one. Often meets major NCD criteria within six months. Look for cognitive decline plus prominent motor symptoms (ataxia, myoclonus, chorea) and possible psychiatric symptoms.

Types to know:

  • Sporadic CJD: Most common, unknown cause
  • Familial CJD: Inherited
  • Acquired CJD: From infected meat (variant) or medical procedures (iatrogenic)

NCD Due to Another Medical Condition

This is your catch-all for NCDs caused by treatable or untreatable medical issues. The course follows the underlying condition.

Potentially reversible causes (critical to identify):

  • Hypoxia
  • Infections
  • Endocrine disorders
  • Normal-pressure hydrocephalus
  • Poisoning
  • Nutritional deficiencies (like B12 deficiency)

This is like your smoke detector going off. Sometimes it's an actual fire requiring major intervention, and sometimes it's just burnt toast that you can fix immediately. Always rule out reversible causes before assuming permanent damage.

Common Misconceptions That Trip Up Test-Takers

Misconception 1: "All neurocognitive disorders involve memory problems first." Reality: Frontotemporal NCD often presents with personality changes while memory stays intact. Lewy body disease prominently features attention and executive problems early on.

Misconception 2: "Delirium and dementia are basically the same thing." Reality: Delirium is acute (hours to days), fluctuates dramatically, and is potentially reversible when you treat the cause. Neurocognitive disorders typically develop gradually and represent progressive, often irreversible decline.

Misconception 3: "Alzheimer's disease can only be diagnosed after death." Reality: Doctors can diagnose Alzheimer's disease while a person is alive. They assess the person's symptoms and can use well-tested biomarkers—signs of disease found in body fluids or brain scans. Examining brain tissue after death can confirm the disease's physical changes. A blood test can help, but it cannot replace the rest of the assessment.

Misconception 4: "Higher rates of Alzheimer's in women prove they're at greater biological risk." Reality: Higher overall rates may simply reflect that women live longer. Age-matched comparisons don't clearly show higher rates in women.

Practice Tips for the EPPP

Create a timing chart: Know which disorders are acute (delirium), which have insidious gradual onset (Alzheimer's, frontotemporal), and which can be rapid (prion disease).

Master the sequence: The order of motor vs. cognitive symptoms distinguishes Lewy body from Parkinson's disease. This comes up repeatedly on exams.

Use the location map: Cortical = memory/language problems. Subcortical = slowing/motor problems. This helps you quickly narrow diagnoses.

Remember the reversibles: If a question describes NCD with a potentially treatable cause (B12 deficiency, normal-pressure hydrocephalus, infection), that's critical information that changes treatment approach.

Know your protein players: Amyloid plaques and tau tangles = Alzheimer's. Lewy bodies = Lewy body disease and Parkinson's. Prions = Creutzfeldt-Jakob.

Practice distinguishing early presentations: What's the FIRST symptom typically noticed? Memory = Alzheimer's. Personality/behavior = frontotemporal. Visual hallucations with fluctuation = Lewy body.

Key Takeaways

  • Delirium is acute, fluctuating, and always has a physiological cause requiring immediate identification and treatment
  • Major NCD significantly impairs independence in daily activities; mild NCD causes noticeable decline but the person remains independent
  • Alzheimer's disease accounts for about 60% to over 90% of dementias (DSM-5-TR), features insidious onset with memory loss typically first, and involves amyloid plaques and tau tangles
  • APOE ε4 is the strongest genetic risk gene for Alzheimer's, but age is the strongest risk factor overall
  • Location matters: Cortical damage produces different symptoms than subcortical damage
  • Frontotemporal NCD is a common cause of early-onset NCD (typical onset in the 50s) and features personality changes or language problems while memory stays relatively intact initially
  • Delirium care starts with nonpharmacological steps, including regular visits from familiar family and friends; antipsychotics don't shorten delirium
  • NCD due to TBI needs an injury with loss of consciousness, posttraumatic amnesia, disorientation, or neurological signs, and the deficits must start right after the injury and persist
  • Timing distinguishes disorders: Lewy body has cognitive symptoms before or with motor symptoms; Parkinson's has motor symptoms first
  • Always rule out reversible causes: Some NCDs from medical conditions can improve with treatment
  • Pseudodementia (depression with cognitive symptoms) responds well to treatment and shows different patterns than true NCD
  • Alzheimer's can be diagnosed during life using a clinical assessment and well-tested signs of disease, called biomarkers. Examining brain tissue after death can confirm the physical changes. A blood test alone is not enough.
  • Anti-amyloid drugs start in the mild cognitive impairment or mild dementia stage, with confirmed amyloid buildup.
  • New headache, confusion, vision changes, or seizures on an anti-amyloid drug can signal ARIA and need prompt medical assessment.
  • Slower decline is not improvement: lecanemab slowed decline by about 27% on the CDR-SB, and both groups still declined.
  • Brexpiprazole is FDA approved for agitation in Alzheimer's dementia, not for amyloid removal or memory loss.

Understanding neurocognitive disorders means seeing patterns, understanding timelines, and connecting brain regions to symptom clusters. Master these connections, and you'll not only ace this section of the EPPP. You'll be prepared to provide competent care throughout your career.

Sources added 2026-10-20

Ready to practice?

Get started in the app